Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N01BB01

Exparel liposomal(bupivacaine)

Acute Pain

Marketing Authorisation Holder: Pacira Ireland Limited

EMA Authorisation: 16/11/2020

INN: bupivacaine

Indication

Exparel liposomal is indicated: in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Exparel liposomal — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.